On June 9, a progress briefing was held in the Beijing Economic-Technological Development Area (Beijing E-Town) to unveil the achievements of the National Medical Artificial Intelligence Pilot-Scale Facility (hereinafter referred to as "Beijing Base") in Beijing. The event showcased a series of milestone results in precision diagnosis and treatment, as well as biopharmaceutical manufacturing, and launched new AI-enabled medical applications that are embedded in clinical practice, extended to primary care, and empowering industry — providing a replicable and scalable model for the deep integration of artificial intelligence and healthcare.

Since its construction began in 2025 at the BioPark, the Beijing Base, supported by the People's Government of Beijing Municipality and Beijing E-Town, has rapidly built a shared capability system covering computing power, data, models, applications, and security. This includes a 384-teraflop domestic intelligent computing resource pool and a trusted data space for medical and health data, among other infrastructure. Leveraging high-quality industry, academia, research, and application resources, as well as the enabling platform of BioPark, the Beijing Base has established a full closed-loop chain spanning technology R&D, clinical validation, industrial translation, and real-world deployment. This has yielded several benchmark achievements in precision diagnosis and biopharmaceutical manufacturing, bringing cutting-edge medical AI technologies out of the lab, into grassroots medical services, and benefiting millions of people.

In the field of precision diagnosis and treatment, Beijing Tongren Hospital, Peking Union Medical College Hospital, Beijing Anzhen Hospital, Peking University First Hospital, Beijing Children's Hospital, and Beijing Tiantan Hospital jointly presented the application and promotion results of medical AI agents developed with the Beijing Base, demonstrating the Base's success in using AI to make quality medical services more equitable and accessible. One example is the blinding eye disease and major chronic disease screening agent developed with Beijing Tongren Hospital. This agent can accurately screen for and provide early warnings of various blinding eye diseases as well as major chronic conditions such as hypertension and diabetes. It has been deployed on a large scale to hundreds of professional health checkup institutions and over a thousand community health service centers nationwide, having served more than 30 million person-times cumulatively. On the day of the briefing, the agent was officially deployed at Lhasa People's Hospital. To date, it has been rolled out across 30 provinces and 140 prefecture-level cities in China, and has been introduced in nine countries across four continents.

In biopharmaceutical manufacturing, the Beijing Base has fully leveraged its platform role, connecting the innovation chain from target discovery to intelligent pharmaceutical manufacturing and injecting new vitality into drug innovation. At the event, the OpenComplex Plus unified drug R&D model, jointly built by the Beijing Base and the Beijing Academy of Artificial Intelligence (BBAI), was released. The unified model integrates four key pharmaceutical processes — target and pocket discovery, structure and pose prediction, affinity and drug resistance assessment, and high-throughput inverse screening — with performance reaching the international leading level. In addition, representatives from China Telecom and Bayer shared insights into the support the Beijing Base has provided for their pharmaceutical innovation efforts. 

At the briefing, the Beijing Future Institute for Artificial Intelligence and Digital Health was officially inaugurated and released its first action plan. The institute will serve as a high-level think tank for the Beijing Base, providing professional intellectual support in areas such as policy research, translation of achievements, and talent cultivation. China Unicom, the entity responsible for building and operating the Beijing Base, also announced a dedicated fund of over RMB 100 million to support the construction of high-quality medical datasets. Targeting medical institutions and ecosystem partners, the fund will focus on six key areas, including clinical diagnosis and treatment, and clinical research.

The progress achieved by the Beijing Base also reflects Beijing E-Town's efforts to accelerate the development of an application demonstration zone for AI in medicine and healthcare. Beijing E-Town is actively undertaking the mission of building the Beijing Base and, relying on BioPark, is creating a core hub for "AI plus healthcare." It promotes the incubation, citywide application, and comprehensive empowerment of AI technologies. BioPark has already attracted 14 multinational pharmaceutical enterprises. Beijing E-Town has also reached agreements with Tsinghua University, Peking University, Capital Medical University, and other leading institutions to jointly advance the construction of an industry-education integration base for life and health, and is accelerating the planning and construction of an international clinical research center. By integrating industry, academia, research, and application resources, the area is becoming fertile ground for innovation in the integrated development of AI and healthcare.

Moving forward, Beijing E-Town will continue to provide strong supporting services, focus on achievement translation and application deployment, accelerate the concentration of high-quality innovation resources, and further clear the bottlenecks in translating "AI plus healthcare" from technological research to large-scale application, contributing to the intelligent upgrading of the medical and healthcare industry.